MANYARA, Anthony Muchai; DAVIES, Philippa; STEWART, Derek; WEIR, Christopher J; YOUNG, Amber E; BLAZEBY, Jane; BUTCHER, Nancy J; BUJKIEWICZ, Sylwia; CHAN, An-Wen; DAWOUD, Dalia; OFFRINGA, Martin; OUWENS, Mario; HROBJARTSSSON, Asbjorn; AMSTUTZ, Alain; BERTOLACCINI, Luca; BRUNO, Vito Domenico; DEVANE, Declan; FARIA, Christina D C M; GILBERT, Peter B; HARRIS, Ray; LASSERE, Marissa; MARINELLI, Lucio; MARKHAM, Sarah; POWERS, John H; REZAEI, Yousef; RICHERT, Laura; SCHWENDICKE, Falk; TERESHCHENKO, Larisa G; THOMA, Achilles; TURAN, Alparslan; WORRALL, Andrew; CHRISTENSEN, Robin; COLLINS, Gary S; ROSS, Joseph S; TAYLOR, Rod S; CIANI, Oriana

doi:10.1136/bmj-2023-078524

Langue

Article de revue

Ce document a été publié dans

BMJ. 2024-07-09, vol. 386, p. e078524

Résumé en anglais

Randomised controlled trials commonly use surrogate endpoints to substitute for a target outcome (outcome of direct interest and relevance to trial participants, clinicians, and other stakeholders—eg, all cause mortality) to improve their efficiency (through shorter trial duration, reduced sample size, and thus lower research costs), or for ethical or practical reasons. But reliance on surrogate endpoints can increase the uncertainty of an intervention’s treatment effect and potential failure to provide adequate information on intervention harms, which has led to calls for improved reporting of trials using surrogate endpoints. This report presents a consensus driven reporting guideline for trials using surrogate endpoints as the primary outcomes—the CONSORT (Consolidated Standards of Reporting Trials) extension checklist: CONSORT-Surrogate. The extension includes nine items modified from the CONSORT 2010 checklist and two new items. Examples and explanations for each item are provided. We recommend that all stakeholders (including trial investigators and sponsors, journal editors and peer reviewers, research ethics reviewers, and funders) use this extension in reporting trial reports using surrogate endpoints. Use of this checklist will improve transparency, interpretation, and usefulness of trial findings, and ultimately reduce research waste.< Réduire

URI

https://oskar-bordeaux.fr/handle/20.500.12278/202506

DOI

http://dx.doi.org/10.1136/bmj-2023-078524

Unités de recherche

Bordeaux Population Health Research Center (BPH) - UMR 1219

Voir/Ouvrir

Métadonnées

Partager cette publication !

Licence d’utilisation du document

Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration

Langue

Ce document a été publié dans

Résumé en anglais

URI

DOI

Unités de recherche